You just read:

Saxenda® (liraglutide [rDNA origin] injection) Demonstrated Significant Improvements in Cardiometabolic Risk Factors Over Three Years Compared With Placebo

News provided by

Novo Nordisk Inc.

04 Apr, 2016, 10:00 ET